Purpose of review This article summarizes the recent developments in the recognition and management of antiphospholipid syndrome (APS). Recent findings Five Task Forces, created as part of the 14th International Congress on antiphospholipid antibodies (aPL), published their systematic reviews. 'For the recognition of APS': the assessment of aPL profile is crucial for risk stratification; lupus anticoagulant positivity, especially in the context of 'triple aPL positivity' displays the highest risk; a panel of criteria and noncriteria aPL tests may help better risk-stratify the aPL-positive in the future. 'For the management of APS': direct oral anticoagulants are not currently recommended; statins ameliorate the proinflammator/thrombotic markers, whereas hydroxychloroquine reduces the risk of thrombosis in experimental models and lupus patients, which justify their use as an adjunctive treatment in refractory cases; B-cell inhibition may have a role in difficult-to-treat patients with hematologic and microthrombotic/angiopathic manifestations; and complement and mammalian targets of rapamycin complex pathway inhibition are promising targets in APS. Summary Warfarin, heparin, and/or antiplatelet drugs are the standard of care for aPL-positive patients. Recent studies suggest novel approaches that target new coagulation and immunomodulatory pathways; mechanistic and/or controlled clinical studies are needed to determine the effectiveness of these novel approaches.
|Titolo:||Recognition and management of antiphospholipid syndrome|
GEROSA, MARIA (Primo)
|Parole Chiave:||Antiphospholipid antibodies; Antiphospholipid syndrome; Lupus anticoagulant; New generation direct oral anticoagulants; Rituximab; Rheumatology|
|Settore Scientifico Disciplinare:||Settore MED/16 - Reumatologia|
|Data di pubblicazione:||2016|
|Digital Object Identifier (DOI):||10.1097/BOR.0000000000000240|
|Appare nelle tipologie:||01 - Articolo su periodico|